People: Agenus Inc (AGEN.W)

Summary

Name	Age	Since	Current Position
Garo Armen	59	1999	Chairman of the Board, Chief Executive Officer
Christine Klaskin	46	2012	Principal Financial Officer, Principal Accounting Officer
Karen Valentine	40	2010	Vice President, Chief Compliance Officer, General Counsel, Secretary
Kerry Wentworth	39		Vice President - Clinical, Regulatory & Quality
Timothy Wright	54	2009	Lead Independent Director
Shalini Sharp	37	2012	Director
Brian Corvese	54	2007	Independent Director
Tom Dechaene	54	2009	Independent Director
Wadih Jordan	77	2003	Independent Director
Jonae Barnes			Vice President - Investor Relations and Corporate Communications

» Insider Trading

Biographies

Name	Description
Garo Armen	Dr. Garo H. Armen, Ph.D., serves as Chairman of the Board, Chief Executive Officer of Agenus Inc., the biotechnology company he co-founded with Pramod Srivastava in 1994. From mid-2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc. Dr. Armen currently serves on the Board of Directors of Protagenic Therapeutics, Inc., a privately held biotechnology company. Dr. Armen served as Senior Vice President of Research for Dean Witter Reynolds (1986–1989), focusing on the chemical and pharmaceutical industries, and with E.F. Hutton & Company as first Vice President (1981–1986). Dr. Armen is also the founder and President of the Children of Armenia Fund, a charitable organization established in 2000 that is dedicated to the positive development of the children and youth of Armenia.
Christine Klaskin	Ms. Christine M. Klaskin will serve as Principal Financial Officer, Principal Accounting Officer of Agenus Inc. She has been appointed as Principal Financial Officer of the Company, effective May 11, 2012. Karen Valentine, Vice President and General Counsel, will direct business development and corporate development transactions. Jonae Barnes, Vice President of Investor Relations and Corporate Communications, will handle all external communication activities, including business development relationships and alliance management. Ms. Klaskin has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Ms. Klaskin is currently a member of the board of directors of American DG Energy Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.
Karen Valentine	Ms. Karen H. Valentine serves as Vice President, Chief Compliance Officer, General Counsel, Secretary of Agenus Inc. Prior to joining Agenus Inc. in 2004, Ms. Valentine was an associate in the biotechnology practice of Palmer & Dodge LLP (now Edwards, Angell, Palmer & Dodge LLP). While at the law firm, she provided corporate law services to a broad range of both public and private corporations, and developed in the areas of licensing and strategic collaborations. Ms. Valentine graduated cum laude with a bachelor’s degree in neuroscience from Colgate University, and received her law degree, magna cum laude, from Boston University School of Law.
Kerry Wentworth	Ms. Kerry A. Wentworth serves as Vice President - Clinical, Regulatory & Quality of Agenus Inc. Before joining Agenus Inc. in 2005, Ms. Wentworth served as senior director of regulatory affairs at Genelabs Technologies, where she was responsible for the business’ regulatory and quality functions. There she focused on the late-stage clinical development and subsequent US and European commercial application filings for the company’s lead product Prestara™. Prior to Genelabs, Ms. Wentworth held various positions in regulatory affairs at Shaman Pharmaceuticals and at Genzyme Corporation. Ms. Wentworth received a BS in pre-veterinary medicine from the University of New Hampshire.
Timothy Wright	Mr. Timothy R. Wright serves as Lead Independent Director of Agenus Inc. Mr. Wright is currently the Director of The Ohio State University Comprehensive Cancer Center Drug Development Institute, a position he has held since September 2011. Additionally Mr. Wright serves as the Chairman and Interim CEO of Curaxis Pharmaceuticals Corporation. Curaxis is a research based company dedicated to finding cures for age-related diseases, including Alzheimer’s Disease and cancer. Mr. Wright formerly served as President of the Imaging Solutions and Pharmaceutical Products Sector of Covidien. Beginning in April 2004, Mr. Wright was interim CEO, President and a member of the Board of Directors of AAI Pharma, a hybrid pharmaceutical, drug delivery/manufacturing, and global clinical research organization. Upon the sale of AAI Pharma’s pharmaceutical assets to Xanodyne Pharmaceuticals Inc., Mr. Wright transitioned to Chief Operating Officer at Xanodyne Pharmaceuticals Inc., a role he maintained until May 2006. Mr. Wright was also President of Elan Bio-Pharmaceuticals and has held several senior management positions with Cardinal Health Inc. and Dupont Merck Pharmaceutical Company.
Shalini Sharp	Ms. Shalini Sharp will serve as Director of Agenus Inc., effective May 11, 2012. Ms. Sharp served as Vice President and Chief Financial Officer of Agenus from 2006 to 2012, and was most recently appointed a member of the Board of Directors effective May 11, 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development activities. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company’s restructuring. With 16 years of industry experience, Ms. Sharp has spearheaded numerous financing and business development transactions that have been critical to the success of Agenus and Elan. Prior to Elan, Ms. Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp holds both a BA, magna cum laude, and MBA, from Harvard University.
Brian Corvese	Mr. Brian Corvese serves as an Independent Director of Agenus Inc. He is President and Founder of Vencor Capital, a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management (“Chancellor”), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert (“Drexel”) as an equity analyst following the chemical and specialty chemical industries and participated in a number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of the National Telecommunications Corporation, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.
Tom Dechaene	Mr. Tom Dechaene serves as an Independent Director of Agenus Inc. Mr. Dechaene is an advisor to various TMT (telecom, media and technology) and life sciences companies. Mr. Dechaene serves on the boards of KBC Group, a financial group listed on the NYSE Euronext, of Transics N.V., a company listed on NYSE Euronext and which develops and markets fleet management solutions for the transport and logistics sector, and of Bourn Hall International Ltd, a private provider of IVF services in India and the MENA region. Mr. Dechaene was a director of Telindus NV, listed on Euronext, from 2005 until its acquisition by Belgacom in 2006. Since 2006 Mr. Dechaene has been a director of the Telindus Foundation in the Netherlands. From 2000 to 2002, Mr. Dechaene was the Chief Financial Officer of SurfCast Inc., a software development company. He was with Deutsche Bank from 1991 through 1999, most recently as a director in the principal investments group within the equity capital markets division. Mr. Dechaene holds a law degree from the Central Exam Commission, Belgium, a masters degree in applied economics from the University of Antwerp, and an MBA from INSEAD, France.
Wadih Jordan	Mr. Wadih Jordan serves as an Independent Director of Agenus Inc. Mr. Jordan is President of NearEast Enterprise, a company marketing pharmaceuticals in Near East markets, including Lebanon, Turkey, Saudi Arabia, Egypt, and the Gulf countries, and has served in such position since 1996. From 1993 to 1995, Mr. Jordan served as a Vice President of Cyanamid International, a research-based life sciences company, and from 1976 to 1993, Mr. Jordan served as a Managing Director within Cyanamid International. Since December 2003, Mr. Jordan has been a trustee of the Board of Directors of the Lebanese American University, located in Beirut, Lebanon, and incorporated under the Board of Regents in New York State. Mr. Jordan received a bachelor’s degree in agriculture at the American University of Beirut, Lebanon, and a certificate in international business from Columbia University.
Jonae Barnes

Basic Compensation

Name	Fiscal Year Total
Garo Armen	1,654,930
Christine Klaskin	354,543
Karen Valentine	470,072
Kerry Wentworth	680,039
Timothy Wright	--
Shalini Sharp	634,754
Brian Corvese	--
Tom Dechaene	--
Wadih Jordan	--
Jonae Barnes	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Garo Armen	1,057,901	446,943
Christine Klaskin	0	0
Karen Valentine	0	0
Kerry Wentworth	0	0
Timothy Wright	0	0
Shalini Sharp	0	0
Brian Corvese	0	0
Tom Dechaene	0	0
Wadih Jordan	0	0
Jonae Barnes	0	0

Insider Trading

Name	Shares Traded	Price
ARMEN GARO H	3,037	$4.35
ARMEN GARO H	3,117	$4.23
ARMEN GARO H	2,964	$4.45
ARMEN GARO H	3,154	$4.18
SHARP SHALINI	288	$4.36
VALENTINE KAREN HIGGINS	417	$4.35
ARMEN GARO H	1,389	$4.35
SHARP SHALINI	625	$4.35
WENTWORTH KERRY A	694	$4.35
KLASKIN CHRISTINE M	417	$4.35
ARMEN GARO H	3,303	$4.00
ARMEN GARO H	250,277	$4.33
ARMEN GARO H	3,320	$3.98
ARMEN GARO H	2,872	$4.60
SHARP SHALINI	288	$4.40
WENTWORTH KERRY A	695	$4.42
KLASKIN CHRISTINE M	417	$4.42
SHARP SHALINI	625	$4.42
ARMEN GARO H	1,388	$4.42
VALENTINE KAREN HIGGINS	417	$4.42
ARMEN GARO H	2,790	$4.73
VALENTINE KAREN HIGGINS	2,410	$0.00
ARMEN GARO H	11,126	$0.00
WENTWORTH KERRY A	5,044	$0.00
KLASKIN CHRISTINE M	1,660	$0.00

» Full list on Insider Trading

People: Agenus Inc (AGEN.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: